Table 1.
Demographic and clinical characteristics (safety population)
| Randomized withdrawal phase | |||
|---|---|---|---|
| Variable | Maintenance phase (N = 643) | Placebo (n = 142) | Solriamfetol (n = 140) |
| Age, years, mean (SD) | 49.3 (14.2) | 50.7 (12.1) | 50.2 (13.2) |
| Male, n (%) | 337 (52.4) | 85 (59.9) | 76 (54.3) |
| Race, n (%) | |||
| White | 506 (78.7) | 110 (77.5) | 112 (80.0) |
| Black/African American | 109 (17.0) | 25 (17.6) | 25 (17.9) |
| Asian | 15 (2.3) | 5 (3.5) | 3 (2.1) |
| Other | 13 (2.0) | 2 (1.4) | 0 |
| BMI, kg/m2, mean (SD) | 31.7 (5.9) | 31.8 (6.0) | 31.9 (5.7) |
| Disease, n (%) | |||
| Narcolepsy | 226 (35.1) | 40 (28.2) | 39 (27.9) |
| OSA | 417 (64.9) | 102 (71.8) | 101 (72.1) |
BMI, body mass index; OSA, obstructive sleep apnea.